Crescendo Bioscience, creators of the Vectra DA blood test to predict the progression of rheumatoid arthritis (RA), is gaining market share in the United States, with its new parent company, Myriad ...
RA, with elevated levels associated with disease onset, disease severity, progression and an increased risk of joint damage. 14-3-3eta is particularly valuable for identifying patients who may benefit ...
Thus far, the promise of precision medicine has been directed largely toward the field of oncology in terms of recommending personalized treatments based on molecular diagnostics tests. But ...
Equipped with a blood test capable of predicting an individual’s response—or lack thereof—to the world’s largest drug class, Scipher Medicine is on its way to cracking the code of rheumatoid arthritis ...
Rheumatoid arthritis (RA) is classified as seropositive or seronegative based on the presence of specific antibodies in the blood, which can influence the severity of symptoms and treatment response.
Q: Can you tell me the name of the blood test that would tell me if I have rheumatoid arthritis? A: Actually, there is no blood test that’ll tell you if you have rheumatoid arthritis — an inflammatory ...
What is rheumatoid arthritis (RA) and how has it traditionally been diagnosed? Rheumatoid arthritis (RA) is an autoimmune disorder that can cause debilitating joint damage. In cases of RA, the immune ...
A marker has been identified by scientists that can indicate a person’s likelihood of suffering from rheumatoid arthritis (RA) years before the onset of the condition. RA occurs when a certain protein ...
One of the many challenges of a rheumatoid arthritis diagnosis is the condition’s variability from patient to patient and over time. This unpredictability also impacts the effectiveness of drugs used ...
Researchers have identified several cytokines, cytokine-related factors, and chemokines that increase significantly prior to rheumatoid arthritis disease onset. These findings confirm those of earlier ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results